Review for Oral Anti-Diabetes Drug Extended
A three-month extension until the end of February has been granted in the FDA’s review period for Novartis AG’s oral anti-diabetes medicine Galvus (vildagliptin).
Diabetes
New Software Features for Insulin Pump Approved
Smiths Medical MD, Inc., of St. Paul, Minn., has received clearance for new software features on its CozMore insulin technology system.
Spironolactone Beneficial In Type 2 Diabetic Nephropathy
Adding spironolactone to an ACE inhibitor or angiotensin II receptor blocker (ARB) is associated with a marked and sustained antiproteinuric effect in type 2 diabetics, researchers in the Netherlands found.
Thiazolidinediones May Increase Bone Loss
PHILADELPHIA—After 15-36 months, diabetics taking thiazolidinediones had increased bone loss at the hip and spine, according to data presented here at the 28th annual meeting of the American Society of Bone and Mineral Resesarch.
Alert Issued for Counterfeit Glucose Test Strips
The FDA issued an alert regarding domestic sales of counterfeit blood glucose test strips for use with various models of LifeScan Inc.’s One Touch brand blood glucose monitors.
Effort to Halt Vendors of Fraudulent Diabetes Cures on Web
As part of an effort by the FDA and the Federal Trade Commission to halt deceptive online advertisements and sales of products misrepresented as diabetes cures or treatments, the agencies have sent approximately 180 letters and advisories to Internet outlets in the United States, Mexico, and Canada.
First in New Class of Diabetes Drugs Cleared
Merck & Co. has received approval of its New Drug Application (See FDA News, April 2006) for Januvia (sitagliptin phosphate) tablets, the first in a new class of drugs known as DPP-4 inhibitors.
Androgen Deprivation Increases Risks
Treatment with a gonadotropin-releasing hormone (GnRH) agonist is associated with increased risks of diabetes, coronary heart disease (CHD), MI, and sudden cardiac death in men with prostate cancer, according to an observational study at Harvard Medical School in Boston.
Enlarged Kidneys Predict Nephropathy
Renal hypertrophy is a major factor in the development of diabetic nephropathy in patients with type 1 diabetes.
Heart Screening Justified In Diabetic Nephropathy Patients
Patients with diabetic nephropathy who are candidates for kidney or kidney- pancreas transplantation should be screened routinely with coronary angiography, researchers in Norway conclude.
-
Loading...
-
Loading...
